Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCADE: HC-1119 vs Enzalutamide in mCRPC
NCT03850795Phase 3Terminated
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Mar 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of deutenzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hinova Pharmaceuticals Inc.. Started Mar 2021; status: terminated.
02
Drugs
deutenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03850795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850795.